BioNexus Gene Lab EBITDA Margin 2019-2024 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

BioNexus Gene Lab ebitda margin from 2019 to 2024. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

BioNexus Gene Lab EBITDA Margin 2019-2024 | BGLC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

BioNexus Gene Lab ebitda margin from 2019 to 2024. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$125.1B
Cencora (COR)	$45B
ICON (ICLR)	$25B
DiDi Global (DIDIY)	$19B
Avantor (AVTR)	$18.4B
Natera (NTRA)	$15.7B
Revvity (RVTY)	$15.4B
Viatris (VTRS)	$14.2B
CochLear (CHEOY)	$12.8B
Solventum (SOLV)	$12.5B
Medpace Holdings (MEDP)	$11.2B
Charles River Laboratories (CRL)	$10.6B
Sonic Healthcare (SKHHY)	$8.8B
Doximity (DOCS)	$7.4B
Bausch + Lomb (BLCO)	$7B
HealthEquity (HQY)	$6.8B
PACS (PACS)	$6.2B
Organon (OGN)	$5.1B
Life Times (LTH)	$4.9B
Sotera Health (SHC)	$4.7B
Surgery Partners (SGRY)	$4.1B
Concentras Parent (CON)	$3B
GoodRx Holdings (GDRX)	$2.8B
BrightSpring Health Services (BTSG)	$2.5B
Ardent Health Partners (ARDT)	$2.4B
Progyny (PGNY)	$2.2B
Alignment Healthcare (ALHC)	$2.2B
Premier (PINC)	$2.1B
Ryman Healthcare (RYHTY)	$1.9B
AMN Healthcare Services Inc (AMN)	$1.8B